Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
International Immunopharmacology|August 20, 2018
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with IpilimumabRichard P Tobin, Kimberly R Jordan, William A Robinson, et al.
The Journal of Surgical Research|December 9, 2008
Increased survival from stage IV melanoma associated with fewer regulatory T CellsJoel M Baumgartner, Rene Gonzalez, Karl D Lewis, et al.
Investigational New Drugs|December 28, 2005
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis, John A Thompson, Jeffrey S Weber, et al.
Journal of Translational Medicine|August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trialsPaolo A Ascierto, Antoni Ribas, James Larkin, et al.
JAMA Oncology|August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical TrialsAxel Hauschild, James Larkin, Antoni Ribas, et al.
Oncotarget|October 21, 2016
Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinomaAnne Lynn S Chang, Karl D Lewis, Sarah T Arron, et al.
JAMA Surgery|January 18, 2013
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy resultEdward L Jones, Teresa S Jones, Nathan W Pearlman, et al.
British Journal of Cancer|August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIMKarl D Lewis, James Larkin, Antoni Ribas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanomaKarl D Lewis, William A Robinson, Martin McCarter, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Pageof 8